· 

Cube Dx develops multiplexed screening for respiratory pathogens - including SARS-Cov-2

After the development of a highly sensitive RT-PCR test for the new coronavirus SARS-Cov-2, Cube Dx is now preparing for the upcoming challenges of the next cold season: a screening for respiratory viruses will enable physicians to rapidly stratify patients with respiratory symptoms.

Cube Dx will use its proven concept of Taqman RT-PCR to provide such a syndromic testing of the most important respiratory viruses. 

The information of the test will simplify the testing of patients and shorten the time to individual therapy. The potential impact of Cube Dx' development convinced the Austrian Agency for Research Funding (FFG) and Cube Dx won a grant for the development of the test within Austria's Covid19 emergency call (https://www.ffg.at/content/COVID19-foerderentscheidung).